Clinical diagnosis for dementia largely identify individuals with advanced disease, at a point where disease modifying therapies will be less effective. In 2014, diagnostic criteria for preclinical Alzheimer’s disease were defined to allow better therapeutic targeting. A similar approach is required for the non-Alzheimer dementias (occurs in more than 50% of dementia patients) of frontotemporal dementia, motor neuron disease and Lewy body diseases including Parkinson’s disease. The Diagnosing Inherited Non-Alzheimer Dementias (DINAD) research group aims to identify preclinical forms of these non-Alzheimer dementias to be able to develop preclinical/early clinical diagnostic criteria for to enable better diagnosis and improvement in treatments.